In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions

On Monday, the company disclosed that the FDA, which is currently reviewing the marketing application for the patch, had questions regarding the patch’s adhesion and efficacy concerns if the patch was not fully adhered to the patient’s skin. Consequently, the FDA advisory committee meeting scheduled for May 15 will not be taking place — although no changes to the FDA’s action date of August 5 were announced.